SL
Therapeutic Areas
Edesa Biotech Pipeline
| Drug | Indication | Phase |
|---|---|---|
| EB05 (paridiprubart) | Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Phase 3 |
| EB01 (daniluromer) | Chronic Allergic Contact Dermatitis | Phase 2b |
| EB06 | Vitiligo | Phase 1 |
| Drug | Indication | Phase |
|---|---|---|
| EB05 (paridiprubart) | Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Phase 3 |
| EB01 (daniluromer) | Chronic Allergic Contact Dermatitis | Phase 2b |
| EB06 | Vitiligo | Phase 1 |